An amino-terminal BRAF deletion accounting for acquired resistance to RAF/EGFR inhibition in colorectal cancer

Although combination therapy with RAF and EGFR inhibitors has improved the survival outcomes of patients with BRAF-mutated colorectal cancer (CRC), acquired resistance invariably develops. The mechanisms of acquired resistance to RAF inhibitors have been largely attributed to activating mutations in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tung, Jack K., Neishaboori, Nastaran, Haraldsdottir, Sigurdis, Suarez, Carlos J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476412/
https://www.ncbi.nlm.nih.gov/pubmed/32669268
http://dx.doi.org/10.1101/mcs.a005140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476412/
https://www.ncbi.nlm.nih.gov/pubmed/32669268
http://dx.doi.org/10.1101/mcs.a005140

Ejemplares similares